Cancer Genetics (CGIX) Lowers IPO Amount to 1.65M Shares

March 11, 2013 2:11 PM EDT
Cancer Genetics (Nasdaq: CGIX) filed an amended registration with the U.S. SEC for an Initial Public Offering of its Common Stock. The company plans to sell 1.65 million shares and sees an offering price of $10 to $12 per share. This compares with the company's previous filing, which called for the sale of 1.85 million shares and sees an offering price of $10 to $12 per share. Prior expectations from the company called for a range of $4 to $6 per share and volume of 5 million shares. The company plans to list on the NASDAQ exchange under the symbol "CGIX."

The offering is being made through Aegis Capital Corp and Feltl and Company.

Cancer Genetics is an early-stage diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve and personalize the diagnosis, prognosis and response to treatment (theranosis) of cancer. The proprietary tests being developed target cancers that are difficult to prognose and predict treatment outcomes by using currently available mainstream techniques. These cancers include hematological, urogenital and HPV-associated cancers.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Add Your Comment